
Weight-Loss Drugs Show Promise but Remain Hard to Access
MANCHESTER, England — While evidence mounts to support the widespread use of both semaglutide (Wegovy) and tirzepatide (Mounjaro) in people with heart failure who need to lose weight, experts at the British Cardiovascular Society (BCS) Annual Conference …